A Study to Evaluate the Effects of Hepatic Impairment on the Pharmacokinetics of Relacorilant

NCT06094725 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

30

Enrollment

INDUSTRY

Sponsor class

Conditions

Hepatic Impairment

Interventions

DRUG: Relacorilant

Sponsor

Corcept Therapeutics